ARTICLE
27 May 2026

LD Hamburg, May 20, 2026, Order On Penalty Payments, UPC_CFI_553/2025

BP
Bardehle Pagenberg

Contributor

BARDEHLE PAGENBERG combines the expertise of attorneys-at-law and patent attorneys. As one of the largest IP firms in Europe, BARDEHLE PAGENBERG advises in all fields of Intellectual Property, including all procedures before the patent and trademark offices as well as litigation before the courts through all instances.
An obligation to refrain from an act also requires a permanent compliance with effective measurements to ensure that the compliance is uninterrupted and permanent, R. 354.4 RoP.
Germany Intellectual Property
Bardehle Pagenberg are most popular:
  • within Privacy, Transport, Food, Drugs, Healthcare and Life Sciences topic(s)

1. Key takeaways

An obligation to refrain from an act also requires a permanent compliance with effective measurements to ensure that the compliance is uninterrupted and permanent, R. 354.4 RoP.

In the absence of any indication to the contrary, the obligation to refrain from an act which has created a continuing disturbance must generally be interpreted as encompassing not only the refraining from such acts, but also the performance of any feasible and reasonable acts necessary to remedy the disturbance. An obligation to refrain from an act is not limited to mere inaction but also encompasses the performance of acts to remedy a previously created disturbance, if compliance with the injunction can be achieved solely by such means (LD Düsseldorf, Order of 18. October 2023 – UPC_CFI_177/2023). In addition, the obligation also requires a permanent compliance with effective measurements to ensure that the compliance is uninterrupted and permanent.

A defendant is obliged to control third-parties which it assigns tasks to or which it grants the possibility to execute changes on behalf of the defendant

2. Division

LD Hamburg

3. UPC number

UPC_CFI_553/2025

4. Type of proceedings

Infringement proceedings; proceedings on penalty payments

5. Parties

Applicant: Occlutech GmbH
Defendants: Lepu Medcial Technology (Bejing) Co., Ltd., Lepu Medical (Europe) Cooperatief U.A.

6. Patent(s)

EP 2 387 951

7. Jurisdictions

UPC

8. Body of legislation / Rules

Art. 82 (4) UPCA; R. 354.4 RoP

Please click here to view the full report.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More